p. 1295−1296
2476-762X
Vol.20/No.5
p. 1297−1298
2476-762X
Vol.20/No.5
p. 1299−1301
2476-762X
Vol.20/No.5
p. 1303−1307
2476-762X
Vol.20/No.5
50%) of colorectal cancer. Methods: This study collects a comprehensivedata from the literature review available from respective journals on dietary intervention and the chemo-protectivemechanisms of a few natural resources in obesity -associated colon cancer based on previous and current studies.Results: In obesity-associated colon cancer, the genes of interest and pathways that are mainly involved includeNFκB, P13K/Akt, and MAPK pathways, and FTO, leptin, Cyclin D, MMPs, and STAT3 genes. Dietary modificationis one of the alternative steps in early prevention of colon cancer. It has been proposed that the components present incertain foods may have the ability to protect against many diseases including the prevention of cancer. Conclusion:There are many factors that lead to obesity-associated colon cancer and the mechanisms behind it is still undergoingintensive research. This review aims to scrutinize research as well as reviews that have been previously reported onobesity associated colorectal cancer and the beneficial effects of including antioxidants-rich foods such as vegetablesand fruits in the diet to reduce the risk of obesity associated colorectal cancer.]]>
p. 1309−1319
2476-762X
Vol.20/No.5
p. 1321−1327
2476-762X
Vol.20/No.5
p. 1329−1337
2476-762X
Vol.20/No.5
p. 1339−1343
2476-762X
Vol.20/No.5
p. 1345−1351
2476-762X
Vol.20/No.5
1705.99 ±55.55 fold, Mean ± SEM, n=3, P- value<0.05), whilst the expression of NIS gene was very restricted (< 0.0008 ± 5.43fold, Mean ± SEM, n=3, P- value<0.05) in them. Also, our results showed that BRAF inhibition affected NIS proteinexpression and localization. Conclusions: Current study showed that the differentiate genes/proteins expression canbe induced in the CSCs via focus on signal transduction pathways and targeting their molecules, that are involved inexpression of these genes/proteins. Therefore, attention to targeting CSCs along with routine thyroid cancer therapy,can help to ATC treatment.]]>
p. 1353−1360
2476-762X
Vol.20/No.5
p. 1361−1368
2476-762X
Vol.20/No.5
p. 1369−1376
2476-762X
Vol.20/No.5
p. 1377−1387
2476-762X
Vol.20/No.5
p. 1389−1392
2476-762X
Vol.20/No.5
p. 1393−1401
2476-762X
Vol.20/No.5
30cigarettes per day (ARR:7.523; SE:7.019; accuracy 95.5%). This study also found that the risk of cancer was significantlyincrease with age (99% CI; ARR: 1.065; SE: 0.026). Conclusions: Cigarette smoking behaviour increased the risk anytypes incident of cancer. Total number >20 cigarettes smoked per day contributes to the incidence of malignant cancer.]]>
p. 1403−1408
2476-762X
Vol.20/No.5
p. 1409−1414
2476-762X
Vol.20/No.5
p. 1415−1420
2476-762X
Vol.20/No.5
p. 1421−1426
2476-762X
Vol.20/No.5
p. 1427−1432
2476-762X
Vol.20/No.5
p. 1433−1436
2476-762X
Vol.20/No.5
p. 1437−1443
2476-762X
Vol.20/No.5
p. 1445−1451
2476-762X
Vol.20/No.5
p. 1453−1456
2476-762X
Vol.20/No.5
p. 1457−1462
2476-762X
Vol.20/No.5
p. 1463−1470
2476-762X
Vol.20/No.5
p. 1471−1474
2476-762X
Vol.20/No.5
p. 1475−1479
2476-762X
Vol.20/No.5
p. 1481−1485
2476-762X
Vol.20/No.5
p. 1487−1495
2476-762X
Vol.20/No.5
p. 1497−1501
2476-762X
Vol.20/No.5
p. 1503−1509
2476-762X
Vol.20/No.5
p. 1511−1518
2476-762X
Vol.20/No.5
p. 1519−1524
2476-762X
Vol.20/No.5
p. 1525−1529
2476-762X
Vol.20/No.5
p. 1531−1536
2476-762X
Vol.20/No.5
100), had inferior progression free survival and overall survival (P=0.5). There was no expression ofCLEC14A in any of the core needle biopsies whereas it was expressed in specimens from mastectomy from the samepatient. Conclusion: This is the first report of MVD in LABC prior to any treatment. The results suggest angiogenesiscould be a prognostic factor in LABC.]]>
p. 1537−1545
2476-762X
Vol.20/No.5
26 kg/m2.Among the participants, 37% were smokers, 39% had diabetes, and 56% had hypertension. The medical cost for stagesI-IV ranged from $4,738 to $6,058 USD, with an estimated average cost of $5,114 USD. Conclusion: Total treatmentcosts per patient are high, especially since they were estimated considering only 7.5 months of treatment. This is thefirst study to estimate the annual cost to treat CC in Mexico and to additionally document the resource pattern use, costby stage of cancer, and the distribution by cost categories.]]>
p. 1547−1554
2476-762X
Vol.20/No.5
p. 1555−1561
2476-762X
Vol.20/No.5
p. 1563−1570
2476-762X
Vol.20/No.5
p. 1571−1577
2476-762X
Vol.20/No.5
p. 1579−1585
2476-762X
Vol.20/No.5
p. 1587−1593
2476-762X
Vol.20/No.5